Figure 1.
Figure 1. Mutation analysis in patients with mutations. (A) Patients in AP. (B) Patients in late-CP. Open circles represent wild-type BCR-ABL sequence. The degree of shading indicates the relative percentage of mutant compared with wild type. T indicates transplantation (refer to Tables 2 and 3 for transplantation details), X indicates that imatinib was withdrawn, terminated lines indicate the month the patient died, and arrows indicate that the patient is alive. R indicates when acquired imatinib resistance was evident. For space considerations, the mutations are shown in the figure with single-letter codes rather than 3-letter codes. For patients with multiple mutations the top circle corresponds to the amino acid with the lowest number, eg, in panel A, patient 1, the top circle corresponds to Gly250Glu and the lower circle Met351Thr. The double shading in panel B, patient 4, represents 2 mutations at the same nucleotide; no wild type was detected.

Mutation analysis in patients with mutations. (A) Patients in AP. (B) Patients in late-CP. Open circles represent wild-type BCR-ABL sequence. The degree of shading indicates the relative percentage of mutant compared with wild type. T indicates transplantation (refer to Tables 2 and 3 for transplantation details), X indicates that imatinib was withdrawn, terminated lines indicate the month the patient died, and arrows indicate that the patient is alive. R indicates when acquired imatinib resistance was evident. For space considerations, the mutations are shown in the figure with single-letter codes rather than 3-letter codes. For patients with multiple mutations the top circle corresponds to the amino acid with the lowest number, eg, in panel A, patient 1, the top circle corresponds to Gly250Glu and the lower circle Met351Thr. The double shading in panel B, patient 4, represents 2 mutations at the same nucleotide; no wild type was detected.

Close Modal

or Create an Account

Close Modal
Close Modal